World Health Organization. Western Pacific Region
|
|
- Helena O’Connor’
- 5 years ago
- Views:
Transcription
1 Basic modules for HCV 1
2 HCV Module 1 Hepatitis C serological markers and virology 2
3 HCV Markers 3 Test Anti HCV (Anti hepatitis C virus antibody) HCV RNA (quantitative or qualitative) (Nucleic acid test) Clinical interpretation Indicates exposure to HCV Does not differentiate between active or resolved infections Remains positive even after successful treatment and clearance of HCV infection Cheap, easy, scalable A very good screening test for HCV infection Qualitative tests: HCV RNA is detectable (positive) or not Quantitative test: Amount of HCV RNA per unit blood Positive test indicates presence of active virus replication Becomes negative after successful HCV treatment Costly, time consuming and require expertise Differentiates between active and resolved infection Used for monitoring treatment and its efficacy
4 HCV Markers 4 Test HCV genotype HCVcAg (Hepatitis C core antigen) Clinical interpretation HCV has several strains which vary from each other genetically Classified based on genomic sequences into genotypes 1 to 6 Virus genotypes vary in sensitivity to some drugs Costly, needs specialized equipment and personnel Can help in deciding appropriate treatment in some situations No use if treatment does not depend on genotype A viral protein, produced only when virus is replicating Positive in unresolved chronic infection Become negative after successful HCV treatment Cheaper and easier than HCV RNA, should be scalable Reasonable and cheaper alternative of HCV RNA test However, may be negative in those with very low HCV RNA (lower sensitivity)
5 Interpretation of HCV serologic test results Anti HCV HCV RNA HCV Ag Interpretation Never infected /+ + + Recent infection Persistent (chronic) infection Previously infected (Infection resolved or cured) HCV antigen test gives the same information as HCV RNA. It has the potential to replace the RNA test currently not widely accepted, but is likely to do so in future 5
6 Testing strategy for chronic HCV infection 6
7 Summary A positive anti HCV test indicates exposure to HCV, which is either active or has resolved Anti HCV remains positive following successful treatment Anti HCV antibody test can be used as a screening test for HCV infection, and has been employed in several different strategies Tests for HCV RNA or HCVcAg serve as confirmatory test, indicate active infection and need for treatment. These are also useful to monitor treatment and confirm cure 7
8 Approaches for detecting HCV infection Mass screening (unselected testing of general population) Targeted screening Birth cohort testing Specific high risk groups Blood donor screening (primarily done for blood safety) 8
9 High risk groups for HCV infection The following group of people are at high risk for acquiring HCV infection People living with HIV Transfusion dependent (hemophilia, thalassemia) People who inject drugs Persons on maintenance hemodialysis High risk sexual practices (MSM, sex workers) 9
10 Who to test for chronic HCV infection Testing approach and population Focused testing in most affected populations General population testing Birth cohort testing Recommendations In all settings, serological testing for HCV antibody be offered to the following individuals Adults and adolescents from populations most affected by HCV infection Adults and children with a clinical suspicion of chronic viral hepatitis In settings with a 2% or 5% HCV antibody seroprevalence,all adults have access to and be offered HCV serological testing General population testing approaches should make use of existing community or facility based testing opportunities or programmes such as HIV or TB clinics, drug treatment services and antenatal clinics. This may be applied to specific identified birth cohorts of older persons at higher risk of infection and morbidity within populations that have an overall lower general prevalence 10 GUIDELINES ON HEPATITIS B AND C TESTING (WHO 2017) P37
11 Initial assessment for chronic hepatitis B and C HBV HCV Chronic infection HBsAg Anti HCV Acute infection Anti HBc IgM HCV RNA, HCcAg etc. (without anti HCV antibody, excluding other hepatitis viruses) 11
12 How to test for chronic HCV infection 12 GUIDELINES ON HEPATITIS B AND C TESTING (WHO 2017) P61
13 HCV Module 2 Extrahepatic manifestations of HCV 13
14 Extrahepatic manifestations HCV infection can lead to extrahepatic manifestations. Extrahepatic manifestations are likely to be affected by treatment. The prevalence of these extrahepatic manifestations is usually independent of the degree of liver fibrosis. Younossi et al
15 Prevalence of comorbidities among persons with HCV infection HCV infection can lead to extrahepatic manifestations. Among HCV infected persons, the three most common comorbidities are: depression (24%); diabetes mellitus (15%); and chronic renal disease (10%). The prevalence of these extrahepatic manifestations is usually independent of the degree of liver fibrosis. 15
16 Cryoglobulinemia One of the most common disorders associated with hepatitis C. A blood disorder caused by cryoglobulins deposited in the small and medium sized blood vessels. Many people are not symptomatic. Affect the skin, kidneys, nerves and joints. 16
17 Depression The various factors contribute to depression. The origins of depression with HCV are most likely a combination of: physiological characteristics of the virus; emotional and physical health of the individual; the extent of a person s social support network; personal beliefs; and available treatment options. 17
18 Diabetes HCV can induce insulin resistance. Curing HCV has been found to improve blood sugar levels. 18
19 Sjogren s Syndrome An autoimmune disease that affects the eyes and mouth, making them dry. Although HCV has not been directly linked to Sjogren s syndrome, it is found more often in people with hepatitis C than in the general population. 19
20 Chronic Renal Disease HCV infection is both a cause and a complication of chronic kidney disease, occurring largely in the context of cryoglobulinemia. Type I membrano proliferative glomerulonephritis associated with cryoglobulinemia is the most common form of kidney disease associated with HCV infection. 20
21 HCV Module 3 Hepatitis C transmission and prevention 21
22 Transmission routes of HCV Health care associated Blood products Unsafe injections Medical procedure (i.e. Needle stick injury) Sexual (HIV positive, men who have sex with men) Vertical: Mother to child (4 8%) Horizontal: Young children, household contacts Persons who inject drugs (PWID) 22
23 Needle stick injury (NSI) The risk of infection due to NSI ~40% 3~10% 0.2~0.5% 23 Alter HJ, Seeff LB, Kaplan PM, McAuliffe VJ, Wright EG, et al. Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. N Engl J Med 1976;295: Alter MJ. Occupational exposure to hepatitis C virus: a dilenma. Infect Control Hosp Epidemiol 1994;15: Artenstein AW, Hicks GB, Goodwin BS Jr., Hilliard JK, Human infection with B virus following a needle stick injury Rev Infec Dis 1991;13: Gerberding JL, Bryant LeBlanc CE, Nelson K, Moss AR, Osmond D, et al. Risk of transmitting the human immunodeficiency virus, cytomegalovirus, and hepatitis B virus to health care workers exposed to patients with AIDS and AIDS related conditions. J Infect Dis 1987;156:1 8.
24 Prevention of HCV transmission Primary prevention No vaccine for hepatitis C Reducing the risk of exposure to the virus in health care setting and higher risk population Seconodary and tertiary prevention Education and counselling on option for care Immunization with Hep A & B vaccines Early and appropriate medical management Regular monitoring for early diagnosis 24
25 Prevention of HCV transmission WHO guidance in health care settings Hand hygiene: including surgical hand preparation, hand washing and use of gloves Safe handling and disposal of sharps and waste Safe cleaning of equipment Testing of donated blood Improved access to safe blood Training of health personnel 25
26 Prevention of HCV transmission WHO recommendations for people who inject drugs Offer people who inject drugs the rapid hepatitis B vaccination regimen Offer people who inject drugs incentives to increase uptake and complete the hepatitis B vaccination Implement sterile needle and syringe programmes that also provide low dead space syringes for distribution to people who inject drugs Offer peer interventions to people who inject drugs to reduce the incidence of viral hepatitis Offer opioid substitution therapy to treat opioid dependence, reduce HCV risk behavior and transmission through injecting drug use, and increase adherence to HCV treatment Integrate the treatment of opioid dependence with medical services for hepatitis 26
27 HCV Module 4 Natural history of Hepatitis C 27
28 Acquisition of HCV infection Usual routes of transmission of HCV infection are: Blood transfusion Unsafe injection practices Healthcare related Injection drug use Nosocomial Unsterile surgical procedures, hemodialysis, tissue transplant Body piercing, tattooing Sexual activity Mother to child 28
29 Natural history of HCV infection Acute HCV infection Resolved infection 15 45% (~25%) Persistent infection 55 85% (~75%) Defined as persistence of HCV for >6 months (this time cut off is arbitrary but well accepted) 29
30 Acute HCV Incubation period: 6 weeks to 6 months Variable manifestations Asymptomatic Mild non specific symptoms Mild clinical jaundice in up to 15% of patients Serum aminotransferase (ALT, AST) levels may be high (up to 10 times upper reference limit) Usually goes unrecognized May be identified in those on high risk and on regular monitoring for HCV infection (e.g. persons on maintenance hemodialysis) 30
31 Diagnosis difficult Acute HCV infection A person with HCV infection and one of the following: Recent change in anti HCV antibody/hcv RNA status (from ve to +ve) Recent jaundice or ALT >10 x ULN (beginning <20 wk ago) J Hepatol 2012; 57:
32 Natural history following acute HCV Persistent or chronic infection A person who continues to have detectable HCV RNA in blood beyond six months after acute infection Resolved infection HCV disappears from the body within 6 months after infection However, anti HCV usually continues to be positive Relapse is rare once RNA is spontaneously cleared Re infection can occur following repeat exposure (e.g. in those who continue to be at high risk: IDU, dialysis) 32
33 Definition HCV infection: Active vs resolved Active = Virus is still present in the host Resolved = No virus in the host (immune system has cleared the infection) Laboratory diagnosis Active = Serum HCV RNA +ve Resolved = Serum HCV RNA ve 33
34 Natural history of HCV infection Acute HCV infection Resolved infection 15 45% (~25%) Persistent infection 55 85% (~75%) Anti HCV HCV RNA +ve ve Anti HCV HCV RNA +ve +ve 34
35 Natural history of HCV infection Infection persistent ~0.3%/year Chronic hepatitis with mild fibrosis ~3%/year Chronic hepatitis with severe fibrosis Liver cirrhosis (~20% in 20 years) ~3%/year ~5%/year Liver cirrhosis (decompensated) Hepatocellular carcinoma Death 35
36 Natural history of chronic hepatitis C Chronic infection leads to long term inflammation Results in fibrosis or scarring Metavir fibrosis stage Fibrosis Nodular regeneration Distortion of architecture Develops in ~20% over a year period 36
37 Prolonged liver injury leads to scarring (fibrosis) Central vein F1 F2 Portal tract F3 F4 Scarring/fibrosis: particularly affect the central vein and portal tracts (blood vessels) 37
38 Summary HCV infection can be either acute or persistent Acute HCV infection usually goes unnoticed A proportion of those with HCV infection clear the virus spontaneously Among those with chronic HCV infection, ~20% develop cirrhosis over years Among those with HCV cirrhosis, ~3% develop HCC every year 38
39 Module review What serological markers are necessary to diagnose acute hepatitis C? What should we assess for the patients with anti HCV antibody positive next? What are the goal and surrogate endpoints of antiviral therapy for chronic HCV infection? Who is candidate for treatment for chronic HCV infection? 39
40 HBV Module 5 Assessment of liver fibrosis 40
41 METAVIR stage Definition No fibrosis Portal fibrosis without septa Liver biopsy METAVIR liver biopsy scoring system F0 F1 F2 F3 F4 Portal fibrosis with septa Numerous septa without cirrhosis Cirrhosis 41 GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION UPDATED VERSION (WHO 2016)
42 Clinical features Indirect tests Diagnosis of cirrhosis Hemogram, especially platelet count Biochemical tests: ALT, AST, albumin Composite measures Imaging FIB 4, APRI, Fibrotest Ultrasound Specialized tests Endoscopy for varices Liver stiffness (elastography) 42
43 Assessing the degree of liver fibrosis Non invasive tests Components Requirements Cost APRI AST, platelets Simple serum and FIB 4 Age, AST, ALT, Platelets hematology test FibroTest ggt, haptoglobin, bilirubin, A1apoprotein, α2 macroglobulin AST; aspartate aminotransferase ALT; alanine aminotransferase APRI; aspartate aminotransferase to platelet ratio index FIB 4; fibrosis 4 score Specialized tests at designed laboratories Fibroscan Transient elastography Dedicated equipment +++ Fibroscan (http.myliverexam.com/en/lexamen fibroscan.html) GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION UPDATED VERSION (WHO 2016)
44 AST Platelet Ratio Index (APRI) AST upper limit of normal: Use 40 IU/L if none specified Platelet count: expressed in terms of X1000/microlitre 44
45 FIB 4 AST/ALT upper limit of normal: Use 40 IU/L if none specified Platelet count: expressed in terms of X1000/microlitre Calculation needs a calculator, a phone App or an online tool 45
46 Cirrhosis versus no cirrhosis 46
47 Cirrhosis versus no cirrhosis In resource constraint settings, two cut off values help in treatment prioritization Values above the high cut off High probability of cirrhosis Values between the lower cut off High certainty that there is no cirrhosis Between the two cut offs Cirrhosis possible but not very certain 47
48 Transient elastography (Fibroscan) 48
49 Transient elastography (Fibroscan) Transducer sends a mechanical shearwave Monitor display of Fibroscan Large explored volume (at least 100 times more than biopsy) 49
50 Transient elastography (Fibroscan) Median Calculated from 10 valid measurement Is used as the final result Inter quartile range (IQR) Spread of the middle half of observations Should be small IQR/median Ratio of IQR to median Indicates variability in different reading High values means large variation If > 30%, implies no reliability 50
51 Fibroscan For liver stiffness measured by transient elastography, several different cut offs have been proposed in different studies and disease conditions A commonly used cut off for cirrhosis: >12.5 kpa 51
52 Fibroscan Advantages Easy, non invasive Can be done in outpatient or community settings Takes <10 minutes to perform Health care staff can be easily trained Limiting factors High cost of equipment Equipment needs regular maintenance/calibration by trained personnel No universal cut off values for specific stages of fibrosis Difficult to measure in very obese 52
53 HCV Module 6 Treatment for Chronic Hepatitis C 53
54 Why treat HCV infection? Delay the progression of cirrhosis Reduce the incidence of hepatocellular carcinoma Improve quality of life Improve long term survival (reduce death) Potentially, reduce transmission 54
55 Effect of treatment on natural history Chronic HCV, no cirrhosis Halts progression of fibrosis Marked reduction in risk of progression to cirrhosis Marked reduction in risk of HCC? Reversal of fibrosis Chronic HCV with cirrhosis Reduced risk for HCC Reduced risk of decompensation? Reversal of cirrhosis in early stages 55
56 Clinical management of HCV infection 1. Natural history of HCV infection 2. Clinical assessment of persons with chronic hepatitis C 3. Extrahepatic manifestation of HCV 4. Why to treat for HCV 5. Who to treat for HCV 6. How to treat for HCV 7. How to monitor during treatment for HCV 56
57 57
58 Who should be treated for HCV infection? 58
59 Who should be treated for HCV infection? All patients ( 12 years of age) with detectable HCV RNA (Drugs are currently not approved for use at age <12 y) (Also, only some drugs are approved in y age group) 59
60 Clinical management of HCV infection 1. Natural history of HCV infection 2. Clinical assessment of persons with chronic hepatitis C 3. Extrahepatic manifestation of HCV 4. Why to treat for HCV 5. Who to treat for HCV 6. How to treat for HCV 7. How to monitor during treatment for HCV 60
61 Considerations for treatment 61
62 Direct acting Anti viral Drugs (DAAs) DAAs = Drugs that specifically act against hepatitis C virus Three groups depending on mechanism of action NS3 protease inhibitors (.previr) simeprevir NS5B inhibitors (.buvir) sofosbuvir NS5A inhibitors (.asvir) daclatasvir 62
63 HCV infection: Common treatment regimens Interferon based Not recommended Pegylated Interferon plus ribavirin Pegylated interferon plus ribavirin plus sofosbuvir Interferon free, DAA based treatment Recommended NS5B inhibitor (e.g, sofosbuvir/dasabuvir) + NS3 inhibitor (e.g, Glecaprevir) NS5A inhibitor (e.g, ledipasvir/daclatasvir) Both of the above 63
64 DAA regimens as per WHO Guidelines Fixed dose combinations Sofosbuvir + Ledipasvir Sofosbuvir + Velpatasvir Sofosbuvir + Daclatasvir (also separately) Other drugs Ribavirin (in combination with DAA) 64
65 Treatment regimens for HCV infection: WHO Choice of HCV treatment regimen depends on Patient s age Virus genotype Genotype dependent regimens Pan genotypic regimens Cirrhosis or no cirrhosis 65
66 Drug interactions/ Warnings with DAA use Drugs Sofosbuvir (SOF) Daclatasvir (DCV) Ribavirin (RBV) Contraindication / warning Amiodarone co administration Renal failure (egfr < 30 ml/min/1.73m 2 ) Drugs that induce or inhibit activity of CYP3A Pregnancy or unwillingness to use contraception, breastfeeding Severe concurrent medical disease (cardiac failure, COPD) Co administration of didanosine 66
67 General rules for DAA based treatment Genotype 1, 4, 5 and 6 Similar treatment 2 Easy to treat 3 Difficult to treat If cirrhosis present Longer duration (24 weeks) of treatment Addition of ribavirin may provide additional benefit Higher response rate Shorter duration Higher risk of complications and need for monitoring during Rx Higher risk of relapse 67
68 Approach to treatment Anti-HCV +ve HCV RNA test HCV RNA -ve HCV RNA +ve No treatment or follow-up Age years Age 18 years Genotype-specific regimen Pan-genotype regimen 68
69 Approach to treatment in adults Anti HCV +ve, HCV RNA +ve Age >18 years Look for cirrhosis (APRI) No cirrhosis Pan genotypic regimens Cirrhosis Sofosbuvir + velpatasvir 12 weeks Sofosbuvir + velpatasvir 12 weeks Sofosbuvir + daclatasvir 12 weeks Sofosbuvir + daclatasvir 24 weeks Glecaprevir + pibrentasvir 8 weeks Glecaprevir + pibrentasvir 12 weeks Sofosbuvir + daclatasvir 12 weeks * *if the prevalence of genotype 3 is <5% Sofosbuvir + velpatasvir X 12 weeks works both with and without cirrhosis, but may be costlier than other drugs 69
70 Summary of treatment 70
71 Treatment in children and adolescents Anti-HCV +ve, HCV RNA +ve Age y / weight 35 Kg HCV genotype Genotype 2 Genotype 3 Genotype 1, 4, 5 or 6 Sofosbuvir/ribavirin 12 wk Sofosbuvir/ribavirin 24 wk Sofosbuvir/ledipasvir 12 wk 71 Sofosbuvir, ledipasvir and ribavirin are the only drugs approved for use in y age group
72 Pre treatment Assessment Clinical features Laboratory Fibrosis/cirrhosis HCV RNA HCV genotype Cirrhosis Decompensation Hemogram Liver function tests Creatinine Non invasive fibrosis assessment Fibroscan: if available UGI endoscopy, if needed Only if age years 72
73 Outcome of interest Sustained virological response at 12 weeks posttreatment (SVR12) Undetectable HCV RNA at 12 weeks after stopping drugs No cirrhosis ~95 98% Cirrhosis ~80 90% 73
74 HCV Module 7 Monitoring for Chronic Hepatitis C 74
75 75
76 Monitoring While on treatment: All patients Adherence, toxicities Hemoglobin, TLC, platelets (only with IFN or RBV) Liver function tests (esp. if cirrhosis) Creatinine 12 weeks after completion of treatment: All patients Treatment response: HCV RNA (12 weeks after completion) On follow up after SVR: Only in those with cirrhosis Hepatocellular carcinoma Portal hypertension 76
77 Monitoring on HCV treatment 77
World Health Organization. Western Pacific Region
Advanced modules for HCV 1 HCV Module 1 Hepatitis C serological markers and virology 2 HCV Markers 3 Test Anti HCV (Anti hepatitis C virus antibody) HCV RNA (quantitative or qualitative) (Nucleic acid
More informationHepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm
Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, 2018 12:00 pm 1:00 pm Presenters: Thomas E. Freese, PhD, Larissa Mooney, MD, & Rachel McLean, MPH, Chief, Office of Viral Hepatitis
More informationModule 1 Introduction of hepatitis
Module 1 Introduction of hepatitis 1 Training Objectives At the end of the module, trainees will be able to ; Demonstrate improved knowledge of the global epidemiology of the viral hepatitis Understand
More informationCommonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
More informationMeet the Professor: HIV/HCV Coinfection
Meet the Professor: HIV/HCV Coinfection Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Division of Infectious Diseases Center for Clinical Epidemiology and Biostatistics University
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationWorld Health Organization. Western Pacific Region
Standard modules for HBV 1 HBV Module 1 Hepatitis B serological markers and virology 2 Acute hepatitis HAV HBV HCV HDV HEV Case fatality Case fatality Uncommon increases with increases with age age Superinfection
More informationManagement of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER
Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER Objective Epidemiology Screening criteria Appropriate work up Treatment Guidelines
More informationArvind R. Murali, MD Assistant Professor of Medicine Gastroenterology & Hepatology Organ Transplant Center UIHC, Carver College of Medicine
Arvind R. Murali, MD Assistant Professor of Medicine Gastroenterology & Hepatology Organ Transplant Center UIHC, Carver College of Medicine No financial disclosures No conflicts of interest No affiliations
More informationWHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT
WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT October 13, 2016 Reminder - treatment is recommended for all patients with chronic HCV infection Except short life expectancies that cannot be remediated
More informationHepatitis C in Disclosures
Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationHepatitis C Virus (HCV)
Clinical Practice Guidelines Hepatitis C Virus (HCV) OBJECTIVE The purpose is to guide the appropriate diagnosis and management of Hepatitis C Virus (HCV). GUIDELINE These are only guidelines, and are
More informationBrief Review of HIV and Hepatitis C Virus (HCV) Infection (with focus on HCV)
Brief Review of HIV and Hepatitis C Virus (HCV) Infection (with focus on HCV) James Morrill, MD, PhD MGH Charlestown HealthCare Center Massachusetts General Hospital www.mghcme.org Disclosures Neither
More information1/16/2019. Goals of HCV Therapy. Objectives. Treating Hepatitis C and HIV Co Infection. Cure Defined as sustained virologic response (SVR)
HCV ECHO WESTERN STATES HCV ECHO WESTERN STATES Treating Hepatitis C and HIV Co Infection Paulina Deming, Pharm D Associate Professor, College of Pharmacy Assistant Director, Viral Hepatitis Programs,
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy
New York State HCV Provider Webinar Series Side Effects of Therapy Objectives Understand the basics of HCV therapy Review the currently available regimens for treatment of HCV Appreciate side effects related
More informationHEPATITIS C UPDATES. Sanaa S. Said 10 th April, 2014
HEPATITIS C UPDATES Sanaa S. Said 10 th April, 2014 CONTENTS Introduction Epidemiology Transmission and Natural history Kenyan guidelines What is new? References INTRODUCTION Hepacivirus genus, Flaviviridae
More informationPrimary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.
Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Objectives Epidemiology of chronic hepatitis C CDC guidelines on screening or hepatitis C Diagnosing hepatitis
More informationClinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: CP.PHAR.348 Effective Date: 09/17
Clinical Policy: (Mavyret) Reference Number: CP.PHAR.348 Effective Date: 09/17 Last Review Date: 09/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationLearning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.
Learning Objectives: Hepatitis Update ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Upon attendance of this seminar and review of material provided, the attendees will be able to: 1. List hepatitis viruses
More informationUpdates in the Treatment of Hepatitis C
Disclosures Updates in the Treatment of Hepatitis C Arslan Kahloon M.D Assistant Professor of Medicine University of Tennessee, Chattanooga I have no conflicts of interest or financial sponsorship to disclose
More informationLength of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure appropriate
More informationLength of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the medical evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure
More informationThe New World of HCV Therapy
HCV: Assessing the Patient Prior to Treatment: Diagnostic Testing and Strategy JORGE L. HERRERA M.D., MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE, MOBILE, AL The New World of HCV Therapy Interferon-free
More informationTransmission of HCV in the United States (CDC estimate)
Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong
More informationTHE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE
THE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE MARIA SCHINA CONSULTANT PHYSICIAN INTERNAL MEDICINE AND HEPATOLOGY ATHENS EUROCLINIC 10 th INTERNATIONAL CONGRESS OF
More informationHepatitis C: a treatment revolution
Sunday, 10th July 2016 Michaelmas Cay 2 Room Concurrent 11 Health Innovation Hepatitis C: a treatment revolution Dr. Heather McNamee Hepatitis C a treatment revolution Dr Heather McNamee Medical Director
More informationREQUEST FOR PRIOR AUTHORIZATION Hepatitis C Treatments
Fax completed form to: 866-940-7328 Prior Authorization Phone Number: 800-310-6826 IA Medicaid Member ID # Patient name Date of Birth Patient address Patient phone Provider NPI Prescriber name Phone Prescriber
More informationLength of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure appropriate
More informationHepatitis C Update: A Growing Challenge With Evolving Management Solutions
Pts (%) Hepatitis C Update: A Growing Challenge With Evolving Management Solutions A Growing Challenge With Evolving Management Solutions Introduction Magda Houlberg, MD Chief Clinical Officer Howard Brown
More informationNew HCV reimbursement criteria Chronic hepatitis C regardless of fibrosis stage if:
New HCV reimbursement criteria 01-2018 Chronic hepatitis C with F2 fibrosis stage Chronic hepatitis C regardless of fibrosis stage if: HIV-HCV coinfection HBV-HCV coinfection Listed for or post-solid organ
More informationHepatitis C: the 2015 Perspective for the Family Medicine Practitioner
Hepatitis C: the 2015 Perspective for the Family Medicine Practitioner Annie Luetkemeyer, MD Division of HIV,ID & Global Medicine San Francisco General Hospital Disclosures I have received research grant
More informationReview: How to work up your patient with Hepatitis C
Review: How to work up your patient with Hepatitis C You screened your patient, and now the HCV antibody test is positive. What do you do next? The antibody test only means they have been exposed to HCV.
More informationHepatitis C. No disclosures. 1. The USPSTF recommends Hepatitis C screening in which patient populations?
Hepatitis C Jennifer Acosta PA-C No disclosures 1. The USPSTF recommends Hepatitis C screening in which patient populations? a. All adults at least once b. Immigrants to the US and those over age 65 c.
More informationPosition Paper of the Italian Association for the Study of the Liver for the rational use of anti-hcv drugs available in Italy
Position Paper of the Italian Association for the Study of the Liver for the rational use of anti-hcv drugs available in Italy Advisory committee on new drugs for Hepatitis C : Alessio Aghemo (Coordinator)
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Vosevi) Reference Number: CP.HNMC.41 Effective Date: 07.26.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationPatients must have met all of the following inclusion criteria to be eligible for participation in this study.
Supplementary Appendix S1: Detailed inclusion/exclusion criteria Patients must have met all of the following inclusion criteria to be eligible for participation in this study. Inclusion Criteria 1) Willing
More informationNew HCV reimbursement criteria Chronic hepatitis C regardless of fibrosis stage if:
New HCV reimbursement criteria 01-2018 Chronic hepatitis C with F2 fibrosis stage Chronic hepatitis C regardless of fibrosis stage if: HIV-HCV coinfection HBV-HCV coinfection Listed for or post-solid organ
More informationClinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: GA.PMN.24 Product: Medicaid Effective Date: 9/17
Clinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: GA.PMN.24 Product: Medicaid Effective Date: 9/17 Last Review Date: 9/17 Revision Log See Important Reminder at the end of this policy
More informationHepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18
Hepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18 Overview Hepatitis C Virus Prevalence Effects of Hepatitis C Prevention Diagnosis
More informationHepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity. Cody A. Chastain, MD
Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity Cody A. Chastain, MD Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.32 Subject: Harvoni Page: 1 of 9 Last Review Date: December 2, 2016 Harvoni Description Harvoni (ledipasvir
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Harvoni Page: 1 of 7 Last Review Date: June 19, 2015 Harvoni Description Harvoni (ledipasvir &
More informationThe ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses
The ABCs of Viral Hepatitis Diagnosis Ila Singh, M.D., Ph.D. P & S 14-453 is132@columbia.edu Viral Hepatitis Hepatotropic viruses Hepatitis A, B, C, D, E and G viruses Generalized infection plus infection
More informationS401- Updates in the Treatments of Hepatitis B & C
S401- Updates in the Treatments of Hepatitis B & C Ruben Gonzalez-Vallina, MD Director of Gastroenterology Outpatient Initiatives Miami Children s Hospital Miami, Florida Disclosure of Relevant Relationship
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Sovaldi (sofosbuvir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/8/2014 1. Indications Drug Name: Sovaldi
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More informationSandi Mitchell Nurse Educator Clinical Prevention Services BCCDC
Sandi Mitchell Nurse Educator Clinical Prevention Services BCCDC sandi.mitchell@bccdc.ca Hepatitis A, B and C Testing Transmission Treatment What Is Hepatitis? Hepatitis means inflammation of the liver
More informationHepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:
Hepatitis Dr. Mohamed. A. Mahdi Mob: 0123002800 5/2/2019 Hepatitis Hepatitis means the inflammation of the liver. May cause by viruses or bacteria, parasites, radiation, drugs, chemical and toxins (alcohol).
More informationInitial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH
Initial Evaluation for HCV Therapy Hope McGratty PA-C, MPH Conflict of Interest Disclosure Statement None Who are we talking about today? Treatment naïve Chronic infection This patient seems complicated
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio
More informationHEPATITIS C: UPDATE AND MANAGEMENT
HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I
More informationHepatits C Criteria Direct Acting Antiviral Medications
Hepatits C Criteria Direct Acting Antiviral Medications Harvoni-Formulary PA required 1. Is the patient being treated for a funded condition by the Oregon Health Plan? 2. Does the member have a diagnosis
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationHepatitis C. Core slides
Hepatitis C Core slides This material was prepared by the Viral Hepatitis Prevention Board The slides (or subsets) can be reproduced for educational use only, with reference to the original source and
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.32 Subject: Harvoni Page: 1 of 9 Last Review Date: March 18, 2016 Harvoni Description Harvoni (ledipasvir
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationHepatitis STARS Program. Geri Brown, M.D. Associate Professor Department of Internal Medicine October 4, 2003
Hepatitis 2003 STARS Program Geri Brown, M.D. Associate Professor Department of Internal Medicine October 4, 2003 Outline n Hepatitis A Epidemiology and screening Transmission n Hepatitis B Epidemiology
More informationThe Future is Here Now!
HCV Treatment: Assessing the Patient Prior to Treatment. How Will This Change in the Future? JORGE L. HERRERA M.D., FACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE, MOBILE, AL The Future is Here Now!
More informationHepatitis C Policy Discussion
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationNew HCV reimbursement criteria Chronic hepatitis C regardless of fibrosis stage if:
New HCV reimbursement criteria 01-2017 Chronic hepatitis C with F2 fibrosis stage Chronic hepatitis C regardless of fibrosis stage if: HIV-HCV coinfection HBV-HCV coinfection Listed for or post-solid organ
More informationViral Hepatitis: Dr Erana Gray General and Infectious Diseases Physician
Viral Hepatitis: Dr Erana Gray General and Infectious Diseases Physician Outline: Virology HBV + pregnancy HCV + new treatments Cases Hepatitis Foundation HBV: virus HBsAg far in excess of complete virions,
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.32 Subject: Harvoni Page: 1 of 7 Last Review Date: December 3, 2015 Harvoni Description Harvoni (ledipasvir
More informationToronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action
Toronto Declaration: Strategies to control and eliminate viral hepatitis globally A call for coordinated action Hepatitis B National Action Plan All countries should develop a national and/or regional
More informationHepatitis C Policy Discussion
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More information-HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual
2013: HCV Genome -HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual proteins are released from polyprotein
More informationWhat is Hepatitis C Virus (HCV)?
HEPATITIS C VIRUS (HCV) What is Hepatitis C Virus (HCV)? Hepatitis is an inflammation (swelling or tenderness) of the liver. Hepatitis C virus (HCV) is the most common form of viral hepatitis and usually
More informationClinical Policy: Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) Reference Number: GA.PMN.25 Product: Medicaid Effective Date: 9/17
Clinical Policy: Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) Reference Number: GA.PMN.25 Product: Medicaid Effective Date: 9/17 Last Review Date: 9/17 Revision Log See Important Reminder at the end of
More informationSpecial developments in the management of Hepatitis C. Disclosures
Special developments in the management of Hepatitis C Sandeep Mukherjee,MD Division of Gastroenterology CHI Health and Creighton University Medical Center Omaha, NE 68154 Sandeep.Mukherjee@alegent.org
More informationAll Hands on Deck: Taking on Hepatitis C in Tennessee
All Hands on Deck: Taking on Hepatitis C in Tennessee Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu
More informationPhysical Aspects of Substance Misuse in Older People. Jane Collier Consultant Hepatology John Radcliffe Hospital Oxford
Physical Aspects of Substance Misuse in Older People Jane Collier Consultant Hepatology John Radcliffe Hospital Oxford Areas to cover Hepatitis C Curable disease New drugs (goodbye interferon) Drug Interactions
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Mavyret) Reference Number: CP.HNMC.39 Effective Date: 08.15.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationSASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary
April 1, 2017 Bulletin #165 ISSN 1923-0761 SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary Related Information for Prescribers: Only prescribers who have completed
More informationProfessor Mark Nelson. Chelsea and Westminster Hospital, London, UK
Professor Mark Nelson Chelsea and Westminster Hospital, London, UK Treatment should be prioritized Treatment Indicated All naive and experienced pts with liver disease Prioritized Pts with fibrosis (F3)
More informationTreating Hepatitis C in Patients with Advanced Renal Disease
Treating Hepatitis C in Patients with Advanced Renal Disease Seyed Moayed Alavian M.D. Professor of Medicine, Hepatologist alavian@thc.ir Hemodialysis Patients hemodialysis Preventive Strategies Strict
More informationViral Hepatitis. Dr. Abdulwahhab S. Abdullah CABM, FICMS-G&H PROF. DR. SABEHA ALBAYATI CABM,FRCP
Viral Hepatitis Dr. Abdulwahhab S. Abdullah CABM, FICMS-G&H PROF. DR. SABEHA ALBAYATI CABM,FRCP Viral hepatitis Viral hepatitis must be considered in any patient presenting with hepatitis on LFTs (high
More informationThe New World of HCV Therapy
HCV: Assessing the Patient Prior to Treatment: Diagnostic Testing and Strategy JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE, MOBILE, AL The New World of HCV Therapy Interferon-free
More informationViral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a
Viral hepatitis Supervised by: Dr.Gaith presented by: Shaima a & Anas & Ala a Etiology Common: Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Less common: Cytomegalovirus EBV Rare: Herpes
More informationNon-Invasive Testing for Liver Fibrosis
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Non-Invasive Testing for Liver Fibrosis John Scott, MD, MSc Associate Professor, University of Washington Associate Clinic Director, Hep/Liver Clinic, Harborview
More informationHepatitis C (Direct Acting Antiviral Medications for Treatment of Hepatitis C) Fibrosis Score Requirement QUEST Integration
Hepatitis C (Direct Acting Antiviral Medications for Treatment of Hepatitis C) Fibrosis Score Requirement QUEST Integration Policy Number: Original Effective Date: MM.04.036 06/01/2015 Lines of Business:
More informationHepatitis C Update: Screening, Diagnosis, and Treatment
Mountain West AIDS Education and Training Center Hepatitis C Update: Screening, Diagnosis, and Treatment Brian R. Wood, MD (bwood2@uw.edu) Assistant Professor of Medicine, University of Washington Medical
More informationIntegrating Hepatitis C into Drug Treatment Settings
Integrating Hepatitis C into Drug Treatment Settings Substance Use Disorders Statewide Conference August 24, 2017 Pomona, CA Christine Rodriguez, MPH California Department of Public Health 1. Hepatitis
More informationSovaldi (sofosbuvir)
Market DC Sovaldi (sofosbuvir) Override(s) Prior Authorization Quantity Limit Approval Duration Based on Genotype, Treatment status, Cirrhosis status, or Ribavirin Eligibility status **IN, SC, WA Medicaid
More informationOutline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018
Outline Updates in the Clinical Management of Hepatitis B and C Jennifer C. Lai, MD, MBA Transplant Hepatologist Associate Professor of Medicine In Residence University of California, San Francisco Initial
More informationIt is the policy of health plans affiliated with Centene Corporation that Mavyret is medically necessary when the following criteria are met:
Clinical Policy: (Mavyret) Reference Number: CP.CPA.285 Effective Date: 08.15.17 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationHCV care after cure. This program is supported by educational grants from
HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico
More informationCaution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy
Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy Anjana A. Pillai, Emory University Frank A Anania, Emory University Brian L. Pearlman, Emory University
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationHarvoni (sofosbuvir/ledipasvir
Market DC Override(s) Prior Authorization Quantity Limit (sofosbuvir/ledipasvir) Approval Duration Based on Genotype, Treatment status, Baseline HCV RNA status, Cirrhosis status, Transplant status, or
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationHEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38
2016 Annual Morbidity Report HEPATITIS C, ACUTE a Rates calculated based on less than 19 cases or events are considered unreliable b Calculated from: CDC. Notice to Readers: Final 2016 Reports of Nationally
More informationHepatitis C Direct-Acting Antivirals
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the medical evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure
More informationMolina Healthcare of Texas Hepatitis C Drugs (Medicaid)
Texas Standard Prior Authorization Form Addendum Molina Healthcare of Texas Hepatitis C Drugs (Medicaid) This fax machine is located in a secure location as required by HIPAA Regulations. Complete / Review
More informationHepatitis C Best Practice Guidelines For Local Health Departments
Hepatitis C Best Practice Guidelines For Local Health Departments LHDs are responsible for investigating and reporting all physician reported cases of acute hepatitis C (HCV). For clients known to have
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationClinical Policy: Daclatasvir (Daklinza) Reference Number: ERX.SPA.131 Effective Date:
Clinical Policy: (Daklinza) Reference Number: ERX.SPA.131 Effective Date: 10.01.16 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationGUIDELINES ON HEPATITIS B AND C TESTING POLICY BRIEF
NOVEMBER 2016 GUIDELINES ON HEPATITIS B AND C TESTING POLICY BRIEF NOVEMBER 2016 GUIDELINES ON HEPATITIS B AND C TESTING POLICY BRIEF WHO Library Cataloguing-in-Publication Data Guidelines on hepatitis
More informationTransmission. Transmission Counseling
Learning Objectives Upon completion, participants should be able to: Outline critical components of comprehensive care for patients with chronic HCV infection Counsel patients about reasonable expectations
More informationToronto Declaration 2014: Global Strategies to control and eliminate viral hepatitis globally. A call for coordinated action
Toronto Declaration 2014: Global Strategies to control and eliminate viral hepatitis globally A call for coordinated action Disclaimer Toronto declaration is not aiming to reinvent the wheel or interfere
More information